1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Jae Hyun Shin1, Esteban Chaves-Olarte2, Cirle A. Warren3
  • Editors: W. Michael Scheld4, James M. Hughes5, Richard J. Whitley6
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Medicine, Division of Infectious Disease and International Health, University of Virginia, Charlottesville, VA 22908; 2: Centro de Investigación en Enfermedades Tropicales, Facultad de Microbiología, Universidad de Costa Rica, Costa Rica; 3: Department of Medicine, Division of Infectious Disease and International Health, University of Virginia, Charlottesville, VA 22908; 4: Department of Infectious Diseases, University of Virginia Health System, Charlottesville, VA; 5: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA; 6: Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL
  • Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0007-2015
  • Received 13 November 2015 Accepted 04 December 2015 Published 27 May 2016
  • Cirle A. Warren, ca6t@virginia.edu
image of <span class="jp-italic">Clostridium difficile</span> Infection
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Infection, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/4/3/EI10-0007-2015-1.gif /docserver/preview/fulltext/microbiolspec/4/3/EI10-0007-2015-2.gif
  • Abstract:

    is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus that has long been recognized to be the most common etiologic pathogen of antibiotic-associated diarrhea. infection (CDI) is now the most common cause of health care–associated infections in the United States and accounts for 12% of these infections (Magill SS et al., 1198–1208, 2014). Among emerging pathogens of public health importance in the United States, CDI has the highest population-based incidence, estimated at 147 per 100,000 (Lessa FC et al., 825–834, 2015). In a report on antimicrobial resistance, has been categorized by the Centers for Disease Control and Prevention as one of three “urgent” threats (http://www.cdc.gov/drugresistance/threat-report-2013/). Although was first described in the late 1970s, the past decade has seen the emergence of hypertoxigenic strains that have caused increased morbidity and mortality worldwide. Pathogenic strains, host susceptibility, and other regional factors vary and may influence the clinical manifestation and approach to intervention. In this article, we describe the global epidemiology of CDI featuring the different strains in circulation outside of North America and Europe where strain NAP1/027/BI/III had originally gained prominence. The elderly population in health care settings has been disproportionately affected, but emergence of CDI in children and healthy young adults in community settings has, likewise, been reported. New approaches in management, including fecal microbiota transplantation, are discussed.

  • Citation: Shin J, Chaves-Olarte E, Warren C. 2016. Infection. Microbiol Spectrum 4(3):EI10-0007-2015. doi:10.1128/microbiolspec.EI10-0007-2015.

Key Concept Ranking

Antibacterial Agents
0.42782292
0.42782292

References

1. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247–263. [PubMed][CrossRef]
2. Sun X, Savidge T, Feng H. 2010. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) 2:1848–1880. [PubMed][CrossRef]
3. Alcantara C, Stenson WF, Steiner TS, Guerrant RL. 2001. Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. J Infect Dis 184:648–652. [PubMed][CrossRef]
4. Alcantara CS, Jin X-H, Brito GAC, Carneiro-Filho BA, Barrett LJ, Carey RM, Guerrant RL. 2005. Angiotensin II subtype 1 receptor blockade inhibits Clostridium difficile toxin A-induced intestinal secretion in a rabbit model. J Infect Dis 191:2090–2096. [PubMed][CrossRef]
5. Warren CA, Calabrese GM, Li Y, Pawlowski SW, Figler RA, Rieger J, Ernst PB, Linden J, Guerrant RL. 2012. Effects of adenosine A2A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice. BMC Infect Dis 12:13. [PubMed][CrossRef]
6. Guerrant RL, Walker DH, Weller PF (ed). 2011. Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed. Saunders/Elsevier, Edinburgh, Scotland.
7. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. 1997. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 4:719–722. [PubMed]
8. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt W-D, Wehland J, Aktories K. 2009. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 5:e1000626. doi:10.1371/journal.ppat.1000626. [CrossRef]
9. Lanis JM, Barua S, Ballard JD. 2010. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 6:e1001061. doi:10.1371/journal.ppat.1001061. [PubMed][CrossRef]
10. Lanis JM, Heinlen LD, James JA, Ballard JD. 2013. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog 9:e1003523. doi:10.1371/journal.ppat.1003523. [PubMed][CrossRef]
11. Chaves-Olarte E, Löw P, Freer E, Norlin T, Weidmann M, von Eichel-Streiber C, Thelestam M. 1999. A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. J Biol Chem 274:11046–11052. [PubMed][CrossRef]
12. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila V-J. 2013. Extraintestinal Clostridium difficile infections. Clin Infect Dis 57:e148-e153. [PubMed][CrossRef]
13. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. 2003. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 115:543–546. [CrossRef]
14. Mao EJ, Kelly CR, Machan JT. 2015. Racial differences in Clostridium difficile infection rates are attributable to disparities in health care access. Antimicrob Agents Chemother 59:6283–6287. [PubMed][CrossRef]
15. McDonald LC, Owings M, Jernigan DB. 2006. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12:409–415. [PubMed][CrossRef]
16. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. 2005. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26:273–280. [PubMed][CrossRef]
17. Zilberberg MD, Shorr AF, Kollef MH. 2008. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 14:929–931. [PubMed][CrossRef]
18. Labbé A-C, Poirier L, Maccannell D, Louie T, Savoie M, Béliveau C, Laverdière M, Pépin J. 2008. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52:3180–3187. [PubMed][CrossRef]
19. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault A-M, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–2449. [PubMed][CrossRef]
20. Pépin J, Valiquette L, Alary M-E, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472. [PubMed][CrossRef]
21. Kuijper EJ, Coignard B, Tüll P. 2006. ESCMID Study Group for Clostridium difficile, EU Member States, European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2–18. [PubMed][CrossRef]
22. Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmée M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Akerlund T, Virolainen-Julkunen A, Lyytikäinen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, Monnet DL. 2008. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13:18942. [PubMed]
23. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433–2441. [PubMed][CrossRef]
24. Fernandez Canigia L, Nazar J, Arce M, Dadamio J, Smayevsky J, Bianchini H. 2001. Clostridium difficile diarrhea: frequency of detection in a medical center in Buenos Aires, Argentina. Rev Argent Microbiol 33:101–107. [In Spanish.] [PubMed]
25. Souza Dias MB, Yamashiro J, Borrasca VL, Stempliuk VA, Araújo MRE, Costa SF, Levin AS. 2010. Pseudo-outbreak of Clostridium difficile associated diarrhea (CDAD) in a tertiary-care hospital. Rev Inst Med Trop Sao Paulo 52:133–137. [PubMed][CrossRef]
26. Zumbado-Salas R, Gamboa-Coronado MM, Rodríguez-Cavallini E, Chaves-Olarte E. 2008. Clostridium difficile in adult patients with nosocomial diarrhea in a Costa Rican hospital. Am J Trop Med Hyg 79:164–165. [PubMed]
27. Lopardo G, Morfin-Otero R, Moran-Vazquez II, Noriega F, Zambrano B, Luxemburger C, Foglia G, Rivas EE. 2015. Epidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico. Braz J Infect Dis 19:8–14. [PubMed][CrossRef]
28. Spadão F, Gerhardt J, Guimarães T, Dulley F, Almeida JN, Jr, Batista MV, Shikanai-Yasuda MA, Levin AS, Costa SF. 2014. Incidence of diarrhea by Clostridium difficile in hematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death. Rev Inst Med Trop Sao Paulo 56:325–331. [PubMed][CrossRef]
29. Dumyati G, Stevens V, Hannett GE, Thompson AD, Long C, Maccannell D, Limbago B. 2012. Community-associated Clostridium difficile infections, Monroe County, New York, USA. Emerg Infect Dis 18:392–400. [PubMed][CrossRef]
30. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. 2012. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 107:89–95. [PubMed][CrossRef]
31. Pai S, Aliyu SH, Enoch DA, Karas JA. 2012. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS One 7:e51728. doi:10.1371/journal.pone.0051728. [CrossRef]
32. Sandora TJ, Fung M, Flaherty K, Helsing L, Scanlon P, Potter-Bynoe G, Gidengil CA, Lee GM. 2011. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 30:580–584. [PubMed][CrossRef]
33. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC. 2009. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 144:433–439; discussion 439–440. [PubMed][CrossRef]
34. Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH. 2009. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med 37:2583–2589. [PubMed][CrossRef]
35. Balassiano IT, Miranda KR, Boente RF, Pauer H, Oliveira ICM, Santos-Filho J, Amorim ELT, Caniné GA, Souza CF, Gomes MZR, Ferreira EO, Brazier JS, Domingues RMCP. 2009. Characterization of Clostridium difficile strains isolated from immunosuppressed inpatients in a hospital in Rio de Janeiro, Brazil. Anaerobe 15:61–64. [PubMed][CrossRef]
36. Legaria MC, Lumelsky G, Rosetti S. 2003. Clostridium difficile-associated diarrhea from a general hospital in Argentina. Anaerobe 9:113–116. [PubMed][CrossRef]
37. Pires RN, Monteiro AA, Carneiro LC, Baethgen LF, Tavares R, Lincho CS, Park S, Perlin D, Rodrigues Filho EM, Pasqualotto AC. 2014. Clostridium difficile infection in Brazil: a neglected problem? Am J Infect Control 42:459–460. [PubMed][CrossRef]
38. Balassiano IT, Dos Santos-Filho J, de Oliveira MPB, Ramos MC, Japiassu AM, Dos Reis AM, Brazier JS, de Oliveira Ferreira E, Domingues RMCP. 2010. An outbreak case of Clostridium difficile-associated diarrhea among elderly inpatients of an intensive care unit of a tertiary hospital in Rio de Janeiro, Brazil. Diagn Microbiol Infect Dis 68:449–455. [PubMed][CrossRef]
39. Camacho-Ortiz A, Ponce-de-León A, Sifuentes-Osornio J. 2009. Clostridum difficile associated disease in Latin America. Gac Med Mex 145:223–229. [In Spanish.] [PubMed]
40. Quesada-Gómez C, Vargas P, López-Ureña D, Gamboa-Coronado MM, Rodríguez-Cavallini E. 2012. Community-acquired Clostridium difficile NAP1/027-associated diarrhea in an eighteen month old child. Anaerobe 18:581–583. [PubMed][CrossRef]
41. Quesada-Gómez C, Mulvey MR, Vargas P, Gamboa-Coronado MM, Rodríguez C, Rodríguez-Cavillini E. 2013. Isolation of a toxigenic and clinical genotype of Clostridium difficile in retail meats in Costa Rica. J Food Prot 76:348–351. [PubMed][CrossRef]
42. Silva ROS, Santos RLR, Pires PS, Pereira LC, Pereira ST, Duarte MC, de Assis RA, Lobato FCF. 2013. Detection of toxins A/B and isolation of Clostridium difficile and Clostridium perfringens from dogs in Minas Gerais, Brazil. Braz J Microbiol 44:133–137. [PubMed][CrossRef]
43. Silva ROS, Ribeiro de Almeida L, Oliveira Junior CA, de Magalhães Soares DF, Pereira PLL, Rupnik M, Lobato FCF. 2014. Carriage of Clostridium difficile in free-living South American coati (Nasua nasua) in Brazil. Anaerobe 30:99–101. [PubMed][CrossRef]
44. Quesada-Gómez C, Rodríguez C, Gamboa-Coronado MM, Rodríguez-Cavallini E, Du T, Mulvey MR, Villalobos-Zúñiga M, Boza-Cordero R. 2010. Emergence of Clostridium difficile NAP1 in Latin America. J Clin Microbiol 48:669–670. [PubMed][CrossRef]
45. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D’Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD. 2013. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 45:109–113. [PubMed][CrossRef]
46. López-Ureña D, Quesada-Gómez C, Miranda E, Fonseca M, Rodríguez-Cavallini E. 2014. Spread of epidemic Clostridium difficile NAP1/027 in Latin America: case reports in Panama. J Med Microbiol 63:322–324. [PubMed][CrossRef]
47. Aguayo C, Flores R, Lévesque S, Araya P, Ulloa S, Lagos J, Hormazabal JC, Tognarelli J, Ibáñez D, Pidal P, Duery O, Olivares B, Fernández J. 2015. Rapid spread of Clostridium difficile NAP1/027/ST1 in Chile confirms the emergence of the epidemic strain in Latin America. Epidemiol Infect 143:3069–3073. [PubMed][CrossRef]
48. Camacho-Ortiz A, López-Barrera D, Hernández-García R, Galván-De Los Santos AM, Flores-Treviño SM, Llaca-Díaz JM, Maldonado-Garza HJ, Bosques-Padilla FJ, Garza-González E. 2015. First report of Clostridium difficile NAP1/027 in a Mexican hospital. PLoS One 10:e0122627. doi:10.1371/journal.pone.0122627. [CrossRef]
49. Goorhuis A, Legaria MC, van den Berg RJ, Harmanus C, Klaassen CHW, Brazier JS, Lumelsky G, Kuijper EJ. 2009. Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general hospital in Buenos Aires, Argentina. Clin Microbiol Infect 15:1080–1086. [PubMed][CrossRef]
50. Quesada-Gómez C, López-Ureña D, Acuña-Amador L, Villalobos-Zúñiga M, Du T, Freire R, Guzmán-Verri C, del Mar Gamboa-Coronado M, Lawley TD, Moreno E, Mulvey MR, de Castro Brito GA, Rodríguez-Cavallini E, Rodríguez C, Chaves-Olarte E. 2015. Emergence of an outbreak-associated Clostridium difficile variant with increased virulence. J Clin Microbiol 53:1216–1226. [PubMed][CrossRef]
51. Kim H, Jeong SH, Roh KH, Hong SG, Kim JW, Shin M-G, Kim M-N, Shin HB, Uh Y, Lee H, Lee K. 2010. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 30:491–497. [PubMed][CrossRef]
52. Honda H, Yamazaki A, Sato Y, Dubberke ER. 2014. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe 25:5–10. [PubMed][CrossRef]
53. Kato H, Kato N, Watanabe K, Yamamoto T, Suzuki K, Ishigo S, Kunihiro S, Nakamura I, Killgore GE, Nakamura S. 2001. Analysis of Clostridium difficile isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan. J Clin Microbiol 39:1391–1395. [PubMed][CrossRef]
54. Sawabe E, Kato H, Osawa K, Chida T, Tojo N, Arakawa Y, Okamura N. 2007. Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur J Clin Microbiol Infect Dis 26:695–703. [PubMed][CrossRef]
55. Collins DA, Hawkey PM, Riley TV. 2013. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control 2:21. [PubMed][CrossRef]
56. Kim YS, Han DS, Kim YH, Kim WH, Kim JS, Kim HS, Kim HS, Park YS, Song HJ, Shin SJ, Yang SK, Ye BD, Eun CS, Lee KM, Lee SH, Jang BI, Jung SA, Cheon JH, Choi CH, Huh KC. 2013. Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. Epidemiol Infect 141:189–194. [PubMed][CrossRef]
57. Shin B-M, Kuak EY, Yoo HM, Kim EC, Lee K, Kang J-O, Whang DH, Shin J-H. 2008. Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000-2005. J Med Microbiol 57:697–701. [PubMed][CrossRef]
58. Shin B-M, Kuak EY, Yoo SJ, Shin WC, Yoo HM. 2008. Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagn Microbiol Infect Dis 60:333–337. [PubMed][CrossRef]
59. Kim J, Kang JO, Pai H, Choi TY. 2012. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Int J Antimicrob Agents 40:24–29. [PubMed][CrossRef]
60. Hawkey PM, Marriott C, Liu WE, Jian ZJ, Gao Q, Ling TKW, Chow V, So E, Chan R, Hardy K, Xu L, Manzoor S. 2013. Molecular epidemiology of Clostridium difficile infection in a major Chinese hospital: an underrecognized problem in Asia? J Clin Microbiol 51:3308–3313. [PubMed][CrossRef]
61. Galaydick J, Xu Y, Sun L, Landon E, Weber SG, Sun D, Zhou J, Sherer R. 2015. Seek and you shall find: prevalence of Clostridium difficile in Wuhan, China. Am J Infect Control 43:301–302. [PubMed][CrossRef]
62. Chung C-H, Wu C-J, Lee H-C, Yan J-J, Chang C-M, Lee N-Y, Chen P-L, Lee C-C, Hung Y-P, Ko W-C. 2010. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. J Microbiol Immunol Infect 43:119–125. [CrossRef]
63. Lai C-C, Lin S-H, Tan C-K, Liao C-H, Huang Y-T, Hsueh P-R. 2014. Clinical manifestations of Clostridium difficile infection in a medical center in Taiwan. J Microbiol Immunol Infect 47:491–496. [PubMed][CrossRef]
64. Chia J-H, Lai H-C, Su L-H, Kuo A-J, Wu T-L. 2013. Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of AB+ isolates and increase of A+B+ isolates. PLoS One 8:e75471. doi:10.1371/journal.pone.0075471. [CrossRef]
65. Hung Y-P, Cia C-T, Tsai B-Y, Chen P-C, Lin H-J, Liu H-C, Lee J-C, Wu Y-H, Tsai P-J, Ko W-C. 2015. The first case of severe Clostridium difficile ribotype 027 infection in Taiwan. J Infect 70:98–101. [PubMed][CrossRef]
66. Lai M-J, Chiueh T-S, Huang Z-Y, Lin J-C. 2015. The first Clostridium difficile ribotype 027 strain isolated in Taiwan. J Formos Med Assoc Taiwan 115:210–212. [PubMed][CrossRef]
67. Liao T-L, Lin C-F, Chiou C-S, Shen G-H, Wang J. 2015. Clostridium difficile PCR ribotype 027 emerges in Taiwan. Jpn J Infect Dis 68:338–340. [PubMed][CrossRef]
68. Cheng VCC, Yam WC, Lam OTC, Tsang JLY, Tse EYF, Siu GKH, Chan JFW, Tse H, To KKW, Tai JWM, Ho PL, Yuen KY. 2011. Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis 30:1371–1381. [PubMed][CrossRef]
69. Cheng VCC, Yam WC, Chan JFW, To KKW, Ho PL, Yuen KY. 2009. Clostridium difficile ribotype 027 arrives in Hong Kong. Int J Antimicrob Agents 34:492–493. [PubMed][CrossRef]
70. Warren CA, Labio E, Destura R, Sevilleja JE, Jamias JD, Daez MLO. 2012. Clostridium difficile and Entamoeba histolytica infections in patients with colitis in the Philippines. Trans R Soc Trop Med Hyg 106:424–428. [PubMed][CrossRef]
71. Hassan SA, Othman N, Idris FM, Abdul Rahman Z, Maning N, Abdul Rahman R, Tiong CG. 2012. Prevalence of Clostridium difficile toxin in diarhoeal stool samples of patients from a tertiary hospital in North Eastern Penisular Malaysia. Med J Malaysia 67:402–405. [PubMed]
72. Oyofo BA, Subekti D, Tjaniadi P, Machpud N, Komalarini S, Setiawan B, Simanjuntak C, Punjabi N, Corwin AL, Wasfy M, Campbell JR, Lesmana M. 2002. Enteropathogens associated with acute diarrhea in community and hospital patients in Jakarta, Indonesia. FEMS Immunol Med Microbiol 34:139–146. [PubMed][CrossRef]
73. Rupnik M, Kato N, Grabnar M, Kato H. 2003. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 41:1118–1125. [PubMed][CrossRef]
74. Thamlikitkul V, Danpakdi K, Chokloikaew S. 1996. Incidence of diarrhea and Clostridium difficile toxin in stools from hospitalized patients receiving clindamycin, beta-lactams, or nonantibiotic medications. J Clin Gastroenterol 22:161–163. [PubMed][CrossRef]
75. Wongwanich S, Ramsiri S, Vanasin B, Khowsaphit P, Tantipatayangkul P, Phan-urai R. 1990. Clostridium difficile associated disease in Thailand. Southeast Asian J Trop Med Public Health 21:367–372. [PubMed]
76. Putsathit P, Kiratisin P, Ngamwongsatit P, Riley TV. 2015. Clostridium difficile infection in Thailand. Int J Antimicrob Agents 45:1–7. [PubMed][CrossRef]
77. Kumarasinghe G, Lim YS, Chow C, Bassett DC. 1992. Prevalence of bacterial agents of diarrhoeal disease at the National University Hospital, Singapore and their resistance to antimicrobial agents. Trop Geogr Med 44:229–232. [PubMed]
78. Koh TH, Tan AL, Tan ML, Wang G, Song KP. 2007. Epidemiology of Clostridium difficile infection in a large teaching hospital in Singapore. Pathology 39:438–442. [PubMed][CrossRef]
79. Hsu L-Y, Tan TY, Koh TH, Kwa AL, Krishnan P, Tee NW, Jureen R. 2011. Decline in Clostridium difficile-associated disease rates in Singapore public hospitals, 2006 to 2008. BMC Res Notes 4:77. [PubMed][CrossRef]
80. Lim PL, Ling ML, Lee HY, Koh TH, Tan AL, Kuijper EJ, Goh SS, Low BS, Ang LP, Harmanus C, Lin RT, Krishnan P, James L, Lee CE. 2011. Isolation of the first three cases of Clostridium difficile polymerase chain reaction ribotype 027 in Singapore. Singapore Med J 52:361–364. [PubMed]
81. Ayyagari A, Sharma P, Venkateswarlu, Mehta S, Agarwal KC. 1986. Prevalence of Clostridium difficile in pseudomembranous and antibiotic-associated colitis in north India. J Diarrhoeal Dis Res 4:157–160. [PubMed]
82. Dhawan B, Chaudhry R, Sharma N. 1999. Incidence of Clostridium difficile infection: a prospective study in an Indian hospital. J Hosp Infect 43:275–280. [PubMed][CrossRef]
83. Joshy L, Chaudhry R, Dhawan B. 2009. Detection and characterization of Clostridium difficile from patients with antibiotic-associated diarrhoea in a tertiary care hospital in North India. J Med Microbiol 58:1657–1659. [PubMed][CrossRef]
84. Niyogi SK, Bhattacharya SK, Dutta P, Naik TN, De SP, Sen D, Saha MR, Datta D, Nair GB, Mitra U, Rasaily R, and Chandra Pal S. 1991. Prevalence of Clostridium difficile in hospitalised patients with acute diarrhoea in Calcutta. J Diarrhoeal Dis Res 9:16–19. [PubMed]
85. Ingle M, Deshmukh A, Desai D, Abraham P, Joshi A, Rodrigues C, Mankeshwar R. 2011. Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis. Indian J Gastroenterol 30:89–93. [PubMed][CrossRef]
86. Albert MJ, Faruque AS, Faruque SM, Sack RB, Mahalanabis D. 1999. Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol 37:3458–3464. [PubMed]
87. Thomas C, Stevenson M, Williamson DJ, Riley TV. 2002. Clostridium difficile-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 35:1457–1462. [PubMed][CrossRef]
88. Ferguson JK, Cheng AC, Gilbert GL, Gottlieb T, Korman T, McGregor A, Richards M, Roberts S, Robson J, Van Gessel H, Riley TV. 2011. Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice. Pathology 43:482–487. [PubMed][CrossRef]
89. Slimings C, Armstrong P, Beckingham WD, Bull AL, Hall L, Kennedy KJ, Marquess J, McCann R, Menzies A, Mitchell BG, Richards MJ, Smollen PC, Tracey L, Wilkinson IJ, Wilson FL, Worth LJ, Riley TV. 2014. Increasing incidence of Clostridium difficile infection, Australia, 2011-2012. Med J Aust 200:272–276. [PubMed][CrossRef]
90. Furuya-Kanamori L, Robson J, Soares Magalhães RJ, Yakob L, McKenzie SJ, Paterson DL, Riley TV, Clements ACA. 2014. A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period. J Infect 69:447–455. [PubMed][CrossRef]
91. Jackson T, Nghiem HS, Rowell D, Jorm C, Wakefield J. 2011. Marginal costs of hospital-acquired conditions: information for priority-setting for patient safety programmes and research. J Health Serv Res Policy 16:141–146. [PubMed][CrossRef]
92. Foster NF, Collins DA, Ditchburn SL, Duncan CN, van Schalkwyk JW, Golledge CL, Keed ABR, Riley TV. 2014. Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study. New Microbes New Infect 2:64–71. [PubMed][CrossRef]
93. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Brazier JS, Johnson S, Gerding DN. 2009. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe 15:230–233. [PubMed][CrossRef]
94. Wilson R, Beerbaum P, Giglio S. 2015. Community and hospital acquired Clostridium difficile in South Australia: ribotyping of isolates and a comparison of laboratory detection methods. Lett Appl Microbiol 60:33–36. [PubMed][CrossRef]
95. Knight DR, Giglio S, Huntington PG, Korman TM, Kotsanas D, Moore CV, Paterson DL, Prendergast L, Huber CA, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV. 2015. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14. J Antimicrob Chemother 70:2992–2999. [PubMed][CrossRef]
96. Huber CA, Hall L, Foster NF, Gray M, Allen M, Richardson LJ, Robson J, Vohra R, Schlebusch S, George N, Nimmo GR, Riley TV, Paterson DL. 2014. Surveillance snapshot of Clostridium difficile infection in hospitals across Queensland detects binary toxin producing ribotype UK 244. Commun Dis Intell Q Rep 38:E279–E284. [PubMed]
97. Lim SK, Stuart RL, Mackin KE, Carter GP, Kotsanas D, Francis MJ, Easton M, Dimovski K, Elliott B, Riley TV, Hogg G, Paul E, Korman TM, Seemann T, Stinear TP, Lyras D, Jenkin GA. 2014. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis 58:1723–1730. [PubMed][CrossRef]
98. Eyre DW, Tracey L, Elliott B, Slimings C, Huntington PG, Stuart RL, Korman TM, Kotsiou G, McCann R, Griffiths D, Fawley WN, Armstrong P, Dingle KE, Walker AS, Peto TE, Crook DW, Wilcox MH, Riley TV. 2015. Emergence and spread of predominantly community-onset Clostridium difficile PCR ribotype 244 infection in Australia, 2010 to 2012. Euro Surveill 20:21059. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21059. [PubMed][CrossRef]
99. Elliott B, Squire MM, Thean S, Chang BJ, Brazier JS, Rupnik M, Riley TV. 2011. New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. J Med Microbiol 60:1108–1111. [PubMed][CrossRef]
100. Riley TV, Thean S, Hool G, Golledge CL. 2009. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust 190:706–708. [PubMed]
101. Richards M, Knox J, Elliott B, Mackin K, Lyras D, Waring LJ, Riley TV. 2011. Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. Med J Aust 194:369–371. [PubMed]
102. Bull AL, Worth LJ, Richards MJ. 2012. Implementation of standardised surveillance for Clostridium difficile infections in Australia: initial report from the Victorian Healthcare Associated Infection Surveillance System. Intern Med J 42:715–718. [PubMed][CrossRef]
103. Samie A, Obi CL, Franasiak J, Archbald-Pannone L, Bessong PO, Alcantara-Warren C, Guerrant RL. 2008. PCR detection of Clostridium difficile triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe District, South Africa. Am J Trop Med Hyg 78:577–585. [PubMed]
104. Lekalakala MR, Lewis E, Hoosen AA. 2010. Clostridium difficile infections in a tertiary hospital: value of surveillance. J Hosp Infect 75:328–329. [PubMed][CrossRef]
105. Kullin B, Meggersee R, D’Alton J, Galvao B, Rajabally N, Whitelaw A, Bamford C, Reid SJ, Abratt VR. 2015. Prevalence of gastrointestinal pathogenic bacteria in patients with diarrhoea attending Groote Schuur Hospital, Cape Town, South Africa. S Afr Med J 105:121–125. [PubMed][CrossRef]
106. Mwachari C, Batchelor BI, Paul J, Waiyaki PG, Gilks CF. 1998. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. J Infect 37:48–53. [PubMed][CrossRef]
107. Zulu I, Kelly P, Mwansa J, Veitch A, Farthing MJ. 2000. Contrasting incidence of Clostridium difficile and other enteropathogens in AIDS patients in London and Lusaka. Trans R Soc Trop Med Hyg 94:167–168. [PubMed][CrossRef]
108. Onwueme K, Fadairo Y, Idoko L, Onuh J, Alao O, Agaba P, Lawson L, Ukomadu C, Idoko J. 2011. High prevalence of toxinogenic Clostridium difficile in Nigerian adult HIV patients. Trans R Soc Trop Med Hyg 105:667–669. [PubMed][CrossRef]
109. Simango C, Uladi S. 2014. Detection of Clostridium difficile diarrhoea in Harare, Zimbabwe. Trans R Soc Trop Med Hyg 108:354–357. [PubMed][CrossRef]
110. Tedesco FJ, Barton RW, Alpers DH. 1974. Clindamycin-associated colitis. A prospective study. Ann Intern Med 81:429–433. [PubMed][CrossRef]
111. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DDK, Sferra TJ, Hernandez AV, Donskey CJ. 2013. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 68:1951–1961. [PubMed][CrossRef]
112. Pakyz AL, Moczygemba LR, Wang H, Stevens MP, Edmond MB. 2015. An evaluation of the association between an antimicrobial stewardship score and antimicrobial usage. J Antimicrob Chemother 70:1588–1591. [PubMed][CrossRef]
113. Slimings C, Riley TV. 2014. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 69:881–891. [PubMed][CrossRef]
114. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. 2015. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am J Gastroenterol 110:381–390, quiz 391. [PubMed][CrossRef]
115. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. 1992. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166:561–567. [PubMed][CrossRef]
116. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, Harrison LH. 2013. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 57:1094–1102. [PubMed][CrossRef]
117. Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L, Ip CLC, Golubchik T, Batty EM, Finney JM, Wyllie DH, Didelot X, Piazza P, Bowden R, Dingle KE, Harding RM, Crook DW, Wilcox MH, Peto TEA, Walker AS. 2013. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369:1195–1205. [PubMed][CrossRef]
118. Kim K-H, Fekety R, Batts DH, Brown D, Cudmore M, Silva J, Jr, Waters D. 1981. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 143:42–50. [CrossRef]
119. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. 1989. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:204–210. [PubMed][CrossRef]
120. Dubberke ER, Reske KA, Noble-Wang J, Thompson A, Killgore G, Mayfield J, Camins B, Woeltje K, McDonald JR, McDonald LC, Fraser VJ. 2007. Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control 35:315–318. [PubMed][CrossRef]
121. Bobulsky GS, Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ. 2008. Clostridium difficile skin contamination in patients with C. difficile-associated disease. Clin Infect Dis 46:447–450. [PubMed][CrossRef]
122. Lucado J, Gould C, Elixhauser A. 2012. Clostridium difficile infections (CDI) in hospital stays, 2009. Statistical brief 124. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Agency for Health Care Policy and Research, Rockville, MD. http://www.ncbi.nlm.nih.gov/books/NBK92613/.
123. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S. 2010. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50:194–201. [PubMed][CrossRef]
124. Pépin J, Valiquette L, Cossette B. 2005. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037–1042. [PubMed][CrossRef]
125. Miniño AM, Murphy SL, Xu J, Kochanek KD. 2011. Deaths: final data for 2008. Natl Vital Stat Rep 59:1–126. [PubMed]
126. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825–834. [PubMed][CrossRef]
127. Henrich TJ, Krakower D, Bitton A, Yokoe DS. 2009. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 15:415–422. [PubMed][CrossRef]
128. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189–193. [PubMed][CrossRef]
129. Pepin J, Alary M-E, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. 2005. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40:1591–1597. [PubMed][CrossRef]
130. Kyne L, Merry C, O’Connell B, Kelly A, Keane C, O’Neill D. 1999. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 28:107–113. [PubMed][CrossRef]
131. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431–455. [PubMed][CrossRef]
132. Kelly CP, Pothoulakis C, LaMont JT. 1994. Clostridium difficile colitis. N Engl J Med 330:257–262. [PubMed][CrossRef]
133. Freiler JF, Durning SJ, Ender PT. 2001. Clostridium difficile small bowel enteritis occurring after total colectomy. Clin Infect Dis. 33:1429–1431. [PubMed][CrossRef]
134. Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, McGregor A, Roberts S, Korman TM, Riley TV, Australasian Society for Infections Diseases. 2011. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust 194:353–358. [PubMed]
135. Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. 2014. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1–26. [PubMed][CrossRef]
136. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. 2013. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478–498, quiz 499. [PubMed][CrossRef]
137. Feuerstadt P, Das R, Brandt LJ. 2014. The evolution of urban C. difficile infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008. Am J Gastroenterol 109:1265–1276. [PubMed][CrossRef]
138. Karas JA, Enoch DA, Aliyu SH. 2010. A review of mortality due to Clostridium difficile infection. J Infect 61:1–8. [PubMed][CrossRef]
139. Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, Xu H, Leffler DA, Kelly CP. 2009. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136:1206–1214. [PubMed][CrossRef]
140. Planche T, Wilcox MH. 2015. Diagnostic pitfalls in Clostridium difficile infection. Infect Dis Clin North Am 29:63–82. [PubMed][CrossRef]
141. Gerding DN, Olson MM, Peterson LR, Teasley DG, Gebhard RL, Schwartz ML, Lee JT, Jr. 1986. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 146:95–100. [PubMed][CrossRef]
142. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O’Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox MH. 2013. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 13:936–945. [PubMed][CrossRef]
143. Berrington A, Settle CD. 2007. Which specimens should be tested for Clostridium difficile toxin? J Hosp Infect 65:280–282. [PubMed][CrossRef]
144. Kundrapu S, Sunkesula VCK, Jury LA, Sethi AK, Donskey CJ. 2012. Utility of perirectal swab specimens for diagnosis of Clostridium difficile infection. Clin Infect Dis 55:1527–1530. [PubMed][CrossRef]
145. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J, Jr. 1995. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16:459–477. [PubMed][CrossRef]
146. Am J Health Syst Pharm. 1998. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 55:1407–1411. [PubMed]
147. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586–1590. [PubMed][CrossRef]
148. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–307. [PubMed][CrossRef]
149. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM, Polymer Alternative for CDI Treatment (PACT) investigators. 2014. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59:345–354. [PubMed][CrossRef]
150. Rokas KEE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. 2015. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis 61:934–941. [PubMed][CrossRef]
151. Wenisch JM, Schmid D, Kuo H-W, Allerberger F, Michl V, Tesik P, Tucek G, Laferl H, Wenisch C. 2012. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 56:1974–1978. [PubMed][CrossRef]
152. Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, Johnson M, Bentley S, George RH, Mogg GA. 1978. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. BMJ 2:1667–1669. [PubMed][CrossRef]
153. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. 1989. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 86:15–19. [PubMed][CrossRef]
154. Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier L-C, Valiquette L. 2010. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 10:363. [PubMed][CrossRef]
155. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT, Jr. 1983. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2:1043–1046. [CrossRef]
156. Gerding DN. 1997. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 25(Suppl 2):S206–S210. [PubMed][CrossRef]
157. Apisarnthanarak A, Razavi B, Mundy LM. 2002. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 35:690–696. [PubMed][CrossRef]
158. Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, Teperman S, Boothe H. 2013. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt) 14:532–539. [PubMed][CrossRef]
159. McFarland LV, Elmer GW, Surawicz CM. 2002. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769–1775. [PubMed][CrossRef]
160. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue Y-K, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422–431. [PubMed][CrossRef]
161. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281–289. [PubMed][CrossRef]
162. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55(Suppl 2):S132–S142. [PubMed][CrossRef]
163. Eyre DW, Babakhani F, Griffiths D, Seddon J, Del Ojo Elias C, Gorbach SL, Peto TEA, Crook DW, Walker AS. 2014. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 209:1446–1451. [PubMed][CrossRef]
164. Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. 2012. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 55:351–357. [PubMed][CrossRef]
165. Warren CA, van Opstal EJ, Riggins MS, Li Y, Moore JH, Kolling GL, Guerrant RL, Hoffman PS. 2013. Vancomycin treatment’s association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother 57:689–696. [PubMed][CrossRef]
166. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205. [PubMed][CrossRef]
167. Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RH, Jr. 2008. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Antimicrob Agents Chemother 52:2190–2195. [PubMed][CrossRef]
168. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF, Jr, Garber G, Chasan-Taber S, Davidson DM, Tolevamer Study Investigator Group. 2006. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43:411–420. [PubMed][CrossRef]
169. Louie TJ, Byrne B, Emery J, Ward L, Krulicki W, Nguyen D, Wu K, Cannon K. 2015. Differences of the fecal microflora with Clostridium difficile therapies. Clin Infect Dis 60(Suppl 2):S91–S97. [PubMed][CrossRef]
170. Abougergi MS, Kwon JH. 2011. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 56:19–26. [PubMed][CrossRef]
171. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG. 1983. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 148:93–100. [PubMed][CrossRef]
172. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. 1992. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117:297–302. [PubMed][CrossRef]
173. Zhang F, Luo W, Shi Y, Fan Z, Ji G. 2012. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 107:1755. [PubMed][CrossRef]
174. Gough E, Shaikh H, Manges AR. 2011. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:994–1002. [PubMed][CrossRef]
175. Kassam Z, Lee CH, Yuan Y, Hunt RH. 2013. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 108:500–508. [PubMed][CrossRef]
176. Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, Hohmann EL. 2014. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58:1515–1522. [PubMed][CrossRef]
177. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415. [PubMed][CrossRef]
178. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. 2014. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312:1772–1778. [PubMed][CrossRef]
179. Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, Broussard E, Stollman N, Giovanelli A, Smith B, Yen E, Trivedi A, Hubble L, Kao D, Borody T, Finlayson S, Ray A, Smith R. 2015. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. [Epub ahead of print.] [PubMed][CrossRef]
180. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L. 2014. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109:1065–1071. [PubMed][CrossRef]
181. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercoe E. 2013. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 1:3. [PubMed][CrossRef]
182. Johnston BC, Ma SSY, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, Guyatt GH. 2012. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 157:878–888. [PubMed][CrossRef]
183. Goldenberg JZ, Ma SSY, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. 2013. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 5:CD006095. [CrossRef]
184. Beausoleil M, Fortier N, Guénette S, L’ecuyer A, Savoie M, Franco M, Lachaine J, Weiss K. 2007. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol 21:732–736. [PubMed][CrossRef]
185. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. 2010. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 105:1636–1641. [PubMed][CrossRef]
186. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. 2004. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 7:59–62. [PubMed]
187. Sampalis J, Psaradellis E, Rampakakis E. 2010. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea: a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 6:56–64. [PubMed]
188. Safdar N, Barigala R, Said A, McKinley L. 2008. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. J Clin Pharm Ther 33:663–668. [PubMed][CrossRef]
189. Wenus C, Goll R, Loken EB, Biong AS, Halvorsen DS, Florholmen J. 2008. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 62:299–301. [PubMed][CrossRef]
190. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. 2013. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382:1249–1257. [PubMed][CrossRef]
191. Borriello SP, Barclay FE. 1985. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol 19:339–350. [PubMed][CrossRef]
192. Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M. 1987. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 6:51–53. [PubMed][CrossRef]
193. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. 1998. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351:633–636. [PubMed][CrossRef]
194. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. 2002. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186:1781–1789. [PubMed][CrossRef]
195. Merrigan MM, Sambol SP, Johnson S, Gerding DN. 2003. Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis 188:1922–1927. [PubMed][CrossRef]
196. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. 2012. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56:5224–5229. [PubMed][CrossRef]
197. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. 2015. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313:1719–1727. [PubMed][CrossRef]
198. Kasper AM, Nyazee HA, Yokoe DS, Mayer J, Mangino JE, Khan YM, Hota B, Fraser VJ, Dubberke ER, Centers for Disease Control and Prevention Epicenters Program. 2012. A multicenter study of Clostridium difficile infection-related colectomy, 2000–2006. Infect Control Hosp Epidemiol 33:470–476. [PubMed][CrossRef]
199. Jaber MR, Olafsson S, Fung WL, Reeves ME. 2008. Clinical review of the management of fulminant clostridium difficile infection. Am J Gastroenterol 103:3195–3203, quiz 3204. [PubMed][CrossRef]
200. Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P, West Midlands Research Collaborative. 2012. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 99:1501–1513. [PubMed][CrossRef]
201. Lamontagne F, Labbé A-C, Haeck O, Lesur O, Lalancette M, Patino C, Leblanc M, Laverdière M, Pépin J. 2007. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245:267–272. [PubMed][CrossRef]
202. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. 2002. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235:363–372. [PubMed][CrossRef]
203. Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. 2008. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 143:150–154. [PubMed][CrossRef]
204. Synnott K, Mealy K, Merry C, Kyne L, Keane C, Quill R. 1998. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 85:229–231. [PubMed][CrossRef]
205. Clanton J, Fawley R, Haller N, Daley T, Porter J, Paranjape C, Bonilla H. 2014. Patience is a virtue: an argument for delayed surgical intervention in fulminant Clostridium difficile colitis. Am Surg 80:614–619. [PubMed]
206. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. 2011. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 254:423–427, discussion 427–429. [PubMed][CrossRef]
207. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390–397. [PubMed][CrossRef]
208. Leuzzi R, Adamo R, Scarselli M. 2014. Vaccines against Clostridium difficile. Hum Vaccin Immunother 10:1466–1477. [PubMed][CrossRef]
209. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W, Jr, Nichols R, Edelman R, Bridwell M, Monath TP. 2001. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69:988–995. [PubMed][CrossRef]
210. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764–770. [PubMed][CrossRef]
211. Greenberg RN, Marbury TC, Foglia G, Warny M. 2012. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30:2245–2249. [PubMed][CrossRef]
212. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Béliveau C, Oughton M, Brukner I, Dascal A. 2011. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:1693–1703. [PubMed][CrossRef]
213. Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN. 1998. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 129:1012–1019. [PubMed][CrossRef]
214. Bishara J, Farah R, Mograbi J, Khalaila W, Abu-Elheja O, Mahamid M, Nseir W. 2013. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 57:489–493. [PubMed][CrossRef]
215. Wilcox M, Gerding D, Poxton I, Kelly C, Nathan R, Cornely O, Rahav G, Lee C, Eves K, Pedley A, Tipping R, Guris D, Kartsonis N, Dorr MB. 2015. Bezlotoxumab alone and with actoxumab for prevention of recurrent Clostridium difficile infection in patients on standard of care antibiotics: Integrated results of two Phase 3 studies (MODIFY I and MODIFY II). International Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA.
microbiolspec.EI10-0007-2015.citations
cm/4/3
content/journal/microbiolspec/10.1128/microbiolspec.EI10-0007-2015
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.EI10-0007-2015
2016-05-27
2017-09-20

Abstract:

is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus that has long been recognized to be the most common etiologic pathogen of antibiotic-associated diarrhea. infection (CDI) is now the most common cause of health care–associated infections in the United States and accounts for 12% of these infections (Magill SS et al., 1198–1208, 2014). Among emerging pathogens of public health importance in the United States, CDI has the highest population-based incidence, estimated at 147 per 100,000 (Lessa FC et al., 825–834, 2015). In a report on antimicrobial resistance, has been categorized by the Centers for Disease Control and Prevention as one of three “urgent” threats (http://www.cdc.gov/drugresistance/threat-report-2013/). Although was first described in the late 1970s, the past decade has seen the emergence of hypertoxigenic strains that have caused increased morbidity and mortality worldwide. Pathogenic strains, host susceptibility, and other regional factors vary and may influence the clinical manifestation and approach to intervention. In this article, we describe the global epidemiology of CDI featuring the different strains in circulation outside of North America and Europe where strain NAP1/027/BI/III had originally gained prominence. The elderly population in health care settings has been disproportionately affected, but emergence of CDI in children and healthy young adults in community settings has, likewise, been reported. New approaches in management, including fecal microbiota transplantation, are discussed.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Gross pathology of pseudomembranous colitis. Histopathology of pseudomembranous colitis.

Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0007-2015
Permissions and Reprints Request Permissions
Download as Powerpoint

Tables

Generic image for table
TABLE 1

Risk factors associated with acquisition of

Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0007-2015
Generic image for table
TABLE 2

Emerging trends in the management of infection

Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0007-2015

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error